The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis.
The inclusion of a psychosis risk syndrome has been proposed for the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders. The appropriateness of inclusion of this new risk syndrome in the DSM depends on a careful analysis of both anticipated benefits and risks. Purported benefits include early recognition and case identification, and the hypothetical benefit of preventive intervention of psychotic disorders, for which there is as yet no clear evidence base. However, there is a potential for high rates of false positives particularly at the community level given the difficulty in discriminating mild symptoms from normal variants and low base rates of the syndrome in the general population. High false-positive rates in and of themselves are not necessarily problematic if the risk-benefit ratio is significantly favorable, as with screening for cardiovascular risk factors. For the psychosis risk syndrome, by contrast, there are substantial risks, for both stigma and discrimination, and for unnecessary exposure to antipsychotic medications, which make the high false-positive rate associated with the psychosis risk designation particularly problematic. More research is needed to improve the positive predictive value of the psychosis risk syndrome so that it can be considered for inclusion in future editions of the DSM.
Corcoran
Cheryl M
CM
Department of Psychiatry, New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Cc788@columbia.edu
First
Michael B
MB
Cornblatt
Barbara
B
D014150:Antipsychotic Agents / Q000009:adverse effects; D039721:Diagnostic and Statistical Manual of Mental Disorders; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis* / Q000188:drug therapy; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors
D014150:Antipsychotic Agents
Arch Gen Psychiatry. 2001 Jul;58(7):663-8
11448373
Schizophr Bull. 2003;29(4):703-15
14989408
J Clin Psychiatry. 2007 Apr;68(4):546-57
17474810
Schizophr Res. 2003 Mar 1;60(1):21-32
12505135
Arch Gen Psychiatry. 2010 Feb;67(2):146-54
20124114
Schizophr Bull. 2007 May;33(3):665-72
17255119
Schizophr Bull. 2007 May;33(3):673-81
17404389
Schizophr Bull. 1998;24(1):99-113
9502549
Early Interv Psychiatry. 2009 May;3(2):108-15
19777087
Arch Gen Psychiatry. 2002 Oct;59(10):921-8
12365879
Am J Psychiatry. 2005 Jan;162(1):71-8
15625204
Can J Psychiatry. 1999 May;44(4):335-49
10332574
Schizophr Res. 2005 Mar 1;73(2-3):173-84
15653260
BMJ. 1994 Sep 17;309(6956):699-703
7950522
Circulation. 1998 May 12;97(18):1837-47
9603539
Arch Gen Psychiatry. 2008 Jan;65(1):28-37
18180426
Arch Gen Psychiatry. 2009 Sep;66(9):938-46
19736350
Schizophr Res. 2002 Mar 1;54(1-2):59-65
11853979
Biol Psychiatry. 2007 Feb 15;61(4):551-3
16920077
Br J Psychiatry Suppl. 2007 Dec;51:s96-101
18055946
Arch Gen Psychiatry. 2000 Nov;57(11):1053-8
11074871
Schizophr Res. 2008 Oct;105(1-3):10-7
18765167
Schizophr Bull. 2009 Sep;35(5):894-908
19386578
Am J Psychiatry. 1989 Jul;146(7):892-7
2742015
Aust N Z J Psychiatry. 2009 Feb;43(2):118-28
19153919
Br J Psychiatry Suppl. 1998;172(33):7-13
9764120
Am J Psychiatry. 2006 May;163(5):790-9
16648318
Arch Gen Psychiatry. 1992 Mar;49(3):221-35
1373598
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
16343296
Biol Psychiatry. 2006 May 1;59(9):863-71
16325151
Br J Psychiatry. 2004 Oct;185:291-7
15458988
Schizophr Bull. 2003;29(4):633-51
14989404
Lancet. 1994 Nov 19;344(8934):1398-402
7968076
Harv Rev Psychiatry. 1996 Jan-Feb;3(5):293-5
9384960